Beyond diabetes: T1D Fund’s new remit broadens venture base

How the JDRF T1D Fund is leveraging new insights around autoimmune biology to expand its scope

The JDRF T1D Fund’s investment in ImmunoMolecular Therapeutics this week is the latest example of how the venture philanthropy fund is leveraging new insights around autoimmune biology and the fund’s growing capital base to expand the scope of the fund.

Not only is the fund looking to attract VCs and companies outside of Type I diabetes to invest in the indication, it is now helping diabetes companies broaden their research remit

Read the full 718 word article

User Sign In